NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis $4.22 -0.06 (-1.29%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MEI Pharma Stock (NASDAQ:MEIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MEI Pharma alerts:Sign Up Key Stats Today's Range$4.08▼$4.4550-Day Range$2.36▼$6.8652-Week Range$1.46▼$9.00Volume274,506 shsAverage Volume434,499 shsMarket Capitalization$138.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Read More MEI Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreMEIP MarketRank™: MEI Pharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 865th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MEI Pharma. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MEI Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted40.00% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.09 Percentage of Shares Shorted40.00% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News SentimentN/A News SentimentMEI Pharma has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MEI Pharma this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEI Pharma's insider trading history. Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MEIP Stock News HeadlinesMEI Pharma Secures Loan Agreement with BitGo PrimeSeptember 4 at 12:47 AM | msn.comMEI Pharma Welcomes New Board Member Joshua RiezmanAugust 11, 2025 | theglobeandmail.comHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."September 5 at 2:00 AM | Brownstone Research (Ad)MEI Pharma files to sell 25.3M shares of common stock for holdersAugust 7, 2025 | msn.comMEI Pharma’s Strategic Shift with Litecoin TreasuryJuly 25, 2025 | theglobeandmail.comMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeJuly 22, 2025 | businesswire.comMEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National ExchangeJuly 20, 2025 | msn.comMEI Pharma Shares Surge After Unveiling $100 Million Litecoin Treasury PlanJuly 18, 2025 | msn.comSee More Headlines MEIP Stock Analysis - Frequently Asked Questions How have MEIP shares performed this year? MEI Pharma's stock was trading at $2.46 at the start of the year. Since then, MEIP stock has increased by 73.0% and is now trading at $4.2550. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.39) earnings per share (EPS) for the quarter. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split on Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are MEI Pharma's major shareholders? MEI Pharma's top institutional shareholders include Rangeley Capital LLC (0.03%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III. View institutional ownership trends. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today9/05/2025Next Earnings (Estimated)9/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees100Year Founded2000Profitability EPS (Trailing Twelve Months)($4.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$17.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.00% Return on Assets-64.79% Debt Debt-to-Equity RatioN/A Current Ratio16.78 Quick Ratio16.78 Sales & Book Value Annual Sales$65.30 million Price / Sales2.15 Cash Flow$5.62 per share Price / Cash Flow0.76 Book Value$4.96 per share Price / Book0.86Miscellaneous Outstanding Shares32,840,000Free Float31,813,000Market Cap$140.23 million OptionableOptionable Beta0.38 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MEIP) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.